The Federal Trade Commission (FTC) has settled with dietary supplement marketer TriVita over accusations that the company advertised its cactusbased drink, Nopalea, as providing health benefits such as relieving inflammation without evidence to support the claims. FTC v. TriVita, No. 14-1557 (U.S. Dist. Ct., Ariz., stipulation approval order entered July 11, 2014). The suit, resolved the day after its filing, accused TriVita of manufacturing Nopalea and marketing it as an “anti-inflammatory wellness drink” that scientific studies have shown “reduces or eliminates the effects of inflammation on the body, relieves pain, relieves swelling, improves respiration, and provides skin health benefits,” even though no scientific studies had been conducted to support the claims. Under the settlement order, TriVita can no longer make health claims about Nopalea without clinical tests by qualified researchers supporting them. See FTC Press Release, July 15, 2014.